Research programme: cardiovascular disorders therapies - AbbVie

Drug Profile

Research programme: cardiovascular disorders therapies - AbbVie

Alternative Names: SLV316; SLV329; SLV335; SLV344; SLV345; SLV346; SLV352; SLV356

Latest Information Update: 01 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Solvay
  • Developer AbbVie
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 23 Mar 2010 Preclinical development of SLV 342, SLV 352, SLV 356 & SLV 358 is ongoing
  • 16 Feb 2009 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top